Odyssey Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of next-generation precision medicines for inflammatory diseases and cancer. Founded in 2021 and headquartered in Boston, Massachusetts, the company integrates advanced technologies in drug discovery, including high-throughput screening, structural biology, and artificial intelligence, to target complex biological pathways that were previously considered undruggable. Odyssey's platform aims to create a diverse pipeline of small molecules and protein therapeutics that address significant unmet medical needs. The company's strategy involves a multi-disciplinary approach, combining deep expertise in molecular biology with computational chemistry to accelerate the transition from target identification to clinical development. Their research focuses on modulating the immune system and targeting specific drivers of oncogenesis to provide more effective and safer treatments. Led by a team of experienced drug hunters and scientists, including founder and CEO Gary D. Glick, Odyssey Therapeutics has raised substantial capital to support its ambitious portfolio. By leveraging its integrated technology stack and specialized expertise, the company seeks to redefine the standards of care for patients suffering from life-threatening and chronic conditions through the delivery of highly potent and selective therapeutic candidates.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!